New
York Tamiflu and Relenza
Claims
Roche and GlaxoSmithKline,
makers of Tamiflu and Relenza,
respectively, are facing
pressure to accept a recommendation
by the United State Food
and Drug Administration panel
to put stronger warning labels
on their flu treatments.
Tamiflu, known generally
as oseltamivir, is a pill,
while Relenza, generically
zanamivir, is inhaled, and
the drugs are the two most
frequently used prescription
medications to treat the
flu. The issue of the adequacy
of the warnings was raised
by the FDA after reports
of a dozen deaths of children
in Japan who were taking
Tamiflu. The FDA wants the
companies, particularly Roche,
to add a caution urging close
monitoring of patients for
abnormal behavior such as
delirium or self-injury.
Recently, Roche has indicated
that it has accepted the
FDA recommendation.
Are you seeking
representation for a Tamiflu
or Relenza claim? Contact
us for a free consultation
on your Tamiflu or Relenza
claim today!
Tamiflu’s label already
mentions reports of delirium
and self-injury, but some
of the FDA’s experts
suggested that the language
should mention that several
patients have died as a result
of these abnormal behaviors.
Relenza’s label does
not currently contain any
information relating to adverse
psychiatric events, however,
Relenza does not penetrate
the central nervous system
easily and there is no substantial
evidence that it has caused
problems with recurrent use.
Nearly 600 cases of psychiatric
problems have been reported
in Tamiflu patients, with
75 percent of them coming
from Japan. Five children
there have died after falling
from windows or balconies
or running into traffic,
according to the FDA. There
have also been 55 reports
in the United States; 22
of these reports included
symptoms such as convulsions,
delirium or delusions. Many
in the U.S. relayed stories
similar to those in Japan,
explaining that the children
were trying to flee or escape
through windows, while others
became violent.
“Although there is
still uncertainty about the
cause of the reported abnormal
behavior in patients,” the
FDA posted on its website,
it is prudent to add information
to the labeling, and they
will “continue to monitor” the
drugs.
Have you or
a family member been injured
from taking Tamiflu or Relenza?
Speak to an experienced Tamifu
Lawyer or Relenza Attorney. Contact
us for a free consultation
on your Tamiflu or Relenza
claim today!
Tamiflu and Relenza sales
have netted the companies
over $1 billion in the first
half of 2007, boosted by
government stockpiling of
the drug in the event the
bird flu virus mutates into
a form that can be easily
transmitted among humans.
If you or someone you know
has suffered from adverse
psychiatric injuries, call
an experienced Tamiflu lawyer
or Relenza lawyer today.
Are you seeking representation
for a New York Tamiflu or
Relenza claim? Contact
us for a free consultation
on your Tamiflu or Relenza
claim today!
Michael Gunzburg is
a Tamiflu Lawyer and Relenza
Lawyer in the United States,
and serving the New
York metropolitan area,
including New York City,
Bronx, Brooklyn, Manhattan,
Queens, Staten Island,
Nassau, Suffolk, Westchester,
Rockland and Orange Counties. |
